Monopar Therapeutics
MNPR · XNASCIK 1645469fmd_16BC4H2Q6NPJBMKZXBSH1H9Q7RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | – | – | – | – | 0 | 0 |
| Net interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Research and development | 0 | 1 | 2 | 2 | 4 | 6 | 8 | 6 | 13 | 10 |
| Total operating expenses | 1 | 17 | 3 | 4 | 7 | 9 | 11 | 9 | 16 | 17 |
| Operating income | (1) | (17) | (3) | (4) | (7) | (9) | (11) | (9) | (16) | (17) |
| Interest and investment income | – | – | – | – | – | – | – | 0 | 0 | 3 |
| Income before taxes | – | (17) | (3) | – | – | – | – | (8) | (16) | (14) |
| Income tax expense | 0 | (0) | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (17) | (3) | – | – | – | – | (8) | (16) | (14) |
| Net income | (1) | (17) | (3) | (4) | (6) | (9) | (11) | (8) | (16) | (14) |